These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31829971)

  • 1. Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer.
    Gunawan F; George E; Kotowicz M
    Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
    Body JJ; von Moos R; Niepel D; Tombal B
    BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
    Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
    Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
    Huynh AL; Baker ST; Stewardson AJ; Johnson DF
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.
    Zeng W; Swee DS
    Medicine (Baltimore); 2022 Jul; 101(26):e29731. PubMed ID: 35776989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
    Watthanasuntorn K; Abid H; Gnanajothy R
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.
    Blackley S; Anderson K; Berg J
    J R Coll Physicians Edinb; 2015; 45(2):133-5. PubMed ID: 26181529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab causing severe, refractory hypocalcaemia in a patient with chronic kidney disease.
    Saleem S; Patel S; Ahmed A; Saleem N
    BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29848528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency.
    Daga N; Joseph F
    BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32847872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy.
    Nachankar A; Katyal A; Bansal N; Bishnoi A
    BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35803612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
    Imatoh T; Sai K; Takeyama M; Hori K; Karayama M; Furuhashi K; Segawa K; Kimura M; Kawakami J; Saito Y
    J Clin Pharm Ther; 2019 Feb; 44(1):62-68. PubMed ID: 30144112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis.
    Kanbayashi Y; Sakaguchi K; Hongo F; Ishikawa T; Tabuchi Y; Ukimura O; Takayama K; Taguchi T
    Sci Rep; 2021 Jan; 11(1):978. PubMed ID: 33441770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer.
    Patell K; Ajay K; Al Armashi AR; Bawwab A; Ravakhah K
    J Oncol Pharm Pract; 2022 Apr; 28(3):698-702. PubMed ID: 34693819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan.
    Imatoh T; Sai K; Takeyama M; Segawa K; Yamashita T; Nakashima N; Kataoka Y; Yokoi H; Hiramatsu T; Ohe K; Kimura M; Hori K; Kawakami J; Saito Y
    J Clin Pharm Ther; 2019 Oct; 44(5):788-795. PubMed ID: 31282013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypocalcaemia after denosumab in older people following fracture.
    Chen J; Smerdely P
    Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer.
    Muqeet Adnan M; Bhutta U; Iqbal T; AbdulMujeeb S; Haragsim L; Amer S
    Case Rep Nephrol; 2014; 2014():565393. PubMed ID: 25054070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab-induced hypocalcemia post bariatric surgery-a severe and protracted course: a case report.
    Awang MH; Hatta SFWM; Mohamad AF; Ghani RA
    J Med Case Rep; 2023 Mar; 17(1):73. PubMed ID: 36859300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
    Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
    J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.